Navigation Links
Bioness Inc. Receives FDA Clearance of Its NESS L300 Plus System
Date:5/10/2011

VALENCIA, Calif., May 10, 2011 /PRNewswire/ -- Bioness Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its NESS L300® Plus System. The device combines the Company's NESS L300® Foot Drop System with a thigh stimulation cuff, to provide knee flexion and extension in addition to ankle dorsiflexion during gait. The NESS L300 Plus is intended for persons with upper motor neuron injury or disease resulting from stroke, multiple sclerosis, traumatic brain injury and spinal cord injury. The device also may facilitate muscle re-education, prevent/retard muscle atrophy, maintain or increase range of motion and increase local blood flow.

People with upper motor neuron injuries or diseases often experience gait movement disorders such as foot drop, which is a result of partial leg paralysis. Gait movement disorders not only result in difficulty walking, but may also lead to fatigue, falls or abnormal walking patterns.

The NESS L300 Plus builds on the proven success of Bioness' NESS L300 Foot Drop System and is designed to additionally stimulate the muscles of the thigh. The addition of the thigh stimulation cuff, synchronized with a wireless heel sensor to detect when the foot is on or off the ground, controls the knee, making it easier to walk. Historically, patients have relied on rigid plastic braces which restrict thigh and ankle movements and can lead to additional problems, including increased falls.

"An estimated 12.5 million Americans live with the effects of central nervous system injuries and disorders, and many of these individuals have gait disorders that make it difficult if not impossible for them to walk with freedom," said Thomas G. Fogarty, president & CEO of Bioness. "The NESS L300 Plus will provide physical therapists an additional modality to optimize the patient's course of therapy and allow home users better control over their knee and foot, making it easier to walk. Bioness continues to be committed to bringing innovative solutions to patients and in setting the standard of care with our advanced technology. The NESS L300 Plus represents yet another product in our pursuit of this mission."

Bioness will display the NESS L300 Plus at the upcoming Annual Conference & Exposition of the American Physical Therapy Association (APTA) June 9th – 11th at National Harbor, Maryland in Booth #419. The Company anticipates the device will become commercially available to neurorehabilitation hospitals and centers around the country and to consumers for home use within the coming weeks.

About Bioness Inc.

Bioness provides neuromodulation technologies that help improve lives and restore function for those living with neurological deficits and peripheral pain. The Company develops, manufactures and markets innovative neuromodulation products that help individuals with central nervous system disorders such as stroke, multiple sclerosis, spinal cord injury and traumatic brain injury regain movement in affected limbs. The NESS L300® Foot Drop System and NESS H200® Hand Rehabilitation System, and NESS L300® Plus System are cleared for use by the Food and Drug Administration and are designed to help patients achieve new levels of physical independence and productivity. Individual results vary. Consult with a qualified physician to find out if these products are right for you. Additional information about Bioness can be found at www.bioness.com.

NESS®, NESS L300®, NESS L300® Plus, Bioness® are trademarks of Bioness Inc. | www.bioness.com | Rx Only

Media Contact:

Wendy Ryan/Genevieve Gadenne
Schwartz Communications
781-684-0770
bioness@schwartzcomm.com


'/>"/>
SOURCE Bioness Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hotspur Technologies’ IQCath Catheter Receives CE Mark
2. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
3. Xlumena Receives CE Mark for Revolutionary AXIOS™ Stent and Delivery System
4. MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness
5. SUPERA VERITAS® Receives Regulatory Approval in Australia
6. MAQUET Cardiovascular Receives 510(k) Clearance to Market the CARDIOHELP System in U.S.
7. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
8. STAAR Surgicals nanoFLEX™ Collamer® IOL Receives CE Mark Approval
9. NeoStems Suzhou Erye Pharmaceutical Receives Two Awards at the Chempharm Brand Summit 2011
10. Sound Surgical Technologies PowerX™ Lipo System Receives Clearance from the FDA
11. Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
Breaking Medicine News(10 mins):